« Back to Farmacia Journal 2/2014

PROTEASOME INHIBITION: RECENT ADVANCES IN ANTITUMORAL THERAPY

ELENA CAMELIA STĂNCIULESCU¹, CĂTĂLINA GABRIELA PISOSCHI^1*, GABRIELA RĂU¹, ANA-MARINA ANDREI¹, MONICA BANIȚĂ²

Download Full Article PDF

The major pathway for degradation of intracellular proteins is the ubiquitin-proteasome pathway. There is increasing evidence revealing that the dysregulation of the ubiquitin-proteasome pathway are involved in pathogenesis of many diseases such as cancer and neurodegenerative disorders. Many studies are focused now on developing new drugs that target ubiquitin-proteasome pathway, based on the observation that proteasome inhibition induces apoptosis in many tumor cells. This review exposes recent data concerning the use of proteasome inhibitors in cancer therapy.